Sinew Pharma Past Earnings Performance

Past criteria checks 0/6

Sinew Pharma's earnings have been declining at an average annual rate of -20.6%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been declining at an average rate of 6.6% per year.

Key information

-20.6%

Earnings growth rate

-5.9%

EPS growth rate

Pharmaceuticals Industry Growth	18.5%
Revenue growth rate	-6.6%
Return on equity	-14.1%
Net Margin	n/a
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Companies Like Sinew Pharma (GTSM:6634) Can Afford To Invest In Growth

Mar 11

Sinew Pharma (GTSM:6634) Is In A Strong Position To Grow Its Business

Nov 25

Revenue & Expenses Breakdown

How Sinew Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:6634 Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	0	-178	37	160
31 Mar 24	0	-175	36	156
31 Dec 23	0	-171	35	152
30 Sep 23	0	-158	34	138
30 Jun 23	0	-145	33	124
31 Mar 23	0	-142	33	119
31 Dec 22	0	-140	34	115
30 Sep 22	1	-128	34	102
30 Jun 22	2	-116	33	89
31 Mar 22	4	-104	30	81
31 Dec 21	6	-92	27	73
30 Sep 21	6	-86	24	70
30 Jun 21	6	-81	21	67
31 Mar 21	3	-82	19	67
31 Dec 20	0	-82	18	67
30 Sep 20	0	-81	17	65
30 Jun 20	0	-80	17	64
31 Mar 20	0	-78	17	62
31 Dec 19	0	-76	17	60
30 Sep 19	0	-75	16	59
30 Jun 19	0	-73	16	59
31 Mar 19	0	-74	16	59
31 Dec 18	0	-74	16	60
30 Sep 18	0	-76	15	63
30 Jun 18	0	-77	15	66
31 Mar 18	0	-80	16	67
31 Dec 17	0	-82	17	68
30 Sep 17	0	-80	17	65
30 Jun 17	0	-78	17	63
31 Mar 17	0	-73	16	58
31 Dec 16	0	-67	14	54
31 Dec 15	0	-48	3	45

Quality Earnings: 6634 is currently unprofitable.

Growing Profit Margin: 6634 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 6634 is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.

Accelerating Growth: Unable to compare 6634's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6634 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).

Return on Equity

High ROE: 6634 has a negative Return on Equity (-14.12%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/03 09:19
End of Day Share Price	2025/01/03 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinew Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution